| Identification | Back Directory | [Name]
squalamine | [CAS]
148717-90-2 | [Synonyms]
MSI 1256
Squalamine, >98%
(3β，5α，7α)-3-[[3-((4-Aminobutyl)amino)propyl]amino]cholestane-7，24-diol-24-hydrogen sulfate
Cholestane-7,24-diol,3-[[3-[(4-aminobutyl)amino]propyl]amino]-, 24-(hydrogen sulfate), (3b,5a,7a,24R)-
Cholestane-7,24-diol, 3-[[3-[(4-aminobutyl)amino]propyl]amino]-, 24-(hydrogen sulfate), (3β,5α,7α,24R)- | [Molecular Formula]
C34H65N3O5S | [MDL Number]
MFCD15146903 | [MOL File]
148717-90-2.mol | [Molecular Weight]
627.969 |
| Chemical Properties | Back Directory | [density ]
1.13±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (159.25 mM) | [form ]
Solid | [pka]
-3.49±0.18(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Squalamine is an aminosterol broad-spectrum antibacterial drug present in shark tissue. | [Definition]
ChEBI: Squalamine is a bile acid. | [Biological Activity]
Squalamine (MSI-1256) is a compound with broad-spectrum antiviral activity. | [Synthesis]
Squalamine is isolated from the stomach of spiny horn shark and sea green dog shark. | [in vivo]
Squalamine (2 mg/kg; Intraperitoneal injection; 28 days) inhibits tumor growth in xenografted mice with breast cancer[2].
Squalamine (20 mg; Single application; 0-3 days) has a decolonizing effect on S. aureus on the skin in a mouse model[3].
Squalamine (20-120 mg/kg; Oral gavage; 5 days) restores the function of the mesenteric nervous system in PD mouse models[4]. | Animal Model: | Female athymic mice aged 6 weeks old bearing breast tumor xenografts[2] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection (i.p.); 28 days | | Result: | Significantly retarded the growth of tumors, but the combination with Trastuzumab (HY-P9907) was more effective.
Suppressed MCF-7/HER-2 breast xenograft-associated angiogenesis.
|
| Animal Model: | 10 μL S. aureus suspension(108 cfu/mL) was applied to the female BALB/c mice skin[3] | | Dosage: | 20 mg | | Administration: | Single application; 3 days | | Result: | Reduced S. aureus viable cells by up to 4 log after two days compared with the control.
|
| Animal Model: | PD mice models ( hSNCAA53T mice and PrP-A53T human α-syn overexpressing transgenic mice)[4] | | Dosage: | 20, 40, 80, or 120 mg/kg | | Administration: | Oral gavage (i.g.); 5 days | | Result: | Effectively restored disordered colonic motility in PD mice models.
Increased colonic transit in PrP-A53T mice.
Reduced myenteric intrinsic primary afferent neuron excitability in hSNCAA53T mice.
|
| [storage]
Store at -20°C |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|